Irigenin

Irigenin is a naturally occurring isoflavone found primarily in Iris species plants, including Belamcanda chinensis. It exerts its primary effects by modulating epithelial-mesenchymal transition (EMT) pathways and enhancing antioxidant enzyme activity, making it a subject of interest in oncology and oxidative stress research.

Origin & History

Irigenin is an O-methylated isoflavone, a bioactive flavonoid found in plants of the genus Iris and Belamcanda chinensis. It is extracted using computational drug design and analytical techniques like chromatography from these ethno-medicinal plants of the Western Himalayan region.

Historical & Cultural Context

Irigenin is derived from ethno-medicinal plants of the Western Himalayan region and Belamcanda chinensis. It has been used in traditional systems, though specific historical uses and durations are not detailed in the available research.

Health Benefits

• Demonstrates anti-metastatic effects in lung carcinoma cell lines by modulating EMT (in vitro evidence).[1][2]
• Reduces blue light-induced retinal damage in hARPE-19 cells by enhancing antioxidant defenses (preclinical study).[3]
• Inhibits cell migration and invasion in lung cancer by disrupting integrin interactions (preclinical evidence).[1][2]
• Activates Nrf2/HO-1 pathway to reduce inflammation and apoptosis in osteoarthritis rat models (animal study).[7]
• Enhances cellular antioxidant activity, reducing ROS and promoting mitochondrial health (in vitro evidence).[3]

How It Works

Irigenin disrupts epithelial-mesenchymal transition (EMT) by downregulating key transcription factors such as Snail, Slug, and Vimentin while preserving E-cadherin expression, thereby inhibiting cell migration and invasion in lung carcinoma models. It also activates the Nrf2/HO-1 antioxidant signaling pathway, upregulating superoxide dismutase (SOD) and catalase to mitigate reactive oxygen species (ROS)-induced cellular damage. Additionally, irigenin has been shown to modulate MMP-2 and MMP-9 matrix metalloproteinase activity, which are critical mediators of extracellular matrix degradation and tumor invasiveness.

Scientific Research

No human clinical trials or meta-analyses are available for irigenin. Preclinical studies include anti-metastatic effects in lung carcinoma cell lines (PMID: 27849000) and retinal damage reduction in cell models.

Clinical Summary

Current evidence for irigenin is limited exclusively to in vitro and preclinical cell-based studies, with no published human clinical trials as of 2024. In lung carcinoma cell line experiments (A549 and H1299 cells), irigenin treatment significantly reduced cell migration and invasion at concentrations ranging from 10–80 μM in dose-dependent fashion. A separate preclinical study using hARPE-19 retinal pigment epithelial cells demonstrated that irigenin reduced blue light-induced oxidative damage by enhancing antioxidant enzyme expression. The overall evidence base is early-stage and requires validation in animal models and eventually randomized controlled trials before any clinical conclusions can be drawn.

Nutritional Profile

Irigenin is a naturally occurring isoflavone (specifically an iris isoflavone) isolated primarily from the rhizomes of Iris species (e.g., Iris tectorum, Iris germanica) and some Belamcanda chinensis sources. It is not a macronutrient or micronutrient source itself but functions as a polyphenolic bioactive compound. Molecular weight: 300.26 g/mol (C16H12O6). It contains a characteristic isoflavone backbone with hydroxyl and methoxy substitutions at positions 5, 7, and 3' that contribute to its antioxidant and bioactive properties. No meaningful caloric, protein, fiber, or mineral content is attributable to irigenin in isolation. Bioavailability data is limited; like most isoflavones, intestinal absorption is expected to be moderate and subject to first-pass hepatic metabolism, with glucuronide and sulfate conjugates as likely circulating metabolites. Oral bioavailability is presumed low without formulation enhancement, consistent with the broader isoflavone class (~10–40% in comparable compounds). No established therapeutic dosing range has been validated in human clinical trials.

Preparation & Dosage

No clinically studied dosage ranges are available for irigenin. Preclinical in vitro studies used 10–50 μM for cancer cell inhibition, and related compounds like iridin were dosed at 20–80 mg/kg in mice. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Irigenin pairs well with Quercetin, as both activate the Nrf2/HO-1 antioxidant pathway through overlapping but complementary mechanisms — quercetin's Keap1 disruption may amplify irigenin's HO-1 upregulation additively. Piperine (from black pepper, ~5–20 mg range) is a logical co-ingredient because it inhibits CYP3A4 and UGT enzymes that rapidly metabolize isoflavones, potentially improving irigenin's oral bioavailability significantly (a well-documented mechanism with structurally similar isoflavones like genistein). Additionally, Resveratrol complements irigenin's anti-metastatic profile by independently targeting MMP-2/MMP-9 matrix metalloproteinase activity and interleukin signaling in carcinoma models, providing additive suppression of EMT pathways that irigenin modulates via integrin disruption.

Safety & Interactions

No human safety data or clinical toxicology profiles currently exist for irigenin as an isolated compound, as all studies have been conducted in vitro. Because irigenin is an isoflavone, it may theoretically exhibit weak estrogenic or anti-estrogenic activity by interacting with estrogen receptors (ERα/ERβ), warranting caution in hormone-sensitive conditions such as estrogen receptor-positive breast cancer or endometriosis. Potential interactions with cytochrome P450 enzymes (particularly CYP1A2 and CYP3A4) have not been characterized, so concurrent use with pharmaceuticals metabolized by these enzymes should be approached with caution. Pregnant and breastfeeding women should avoid irigenin supplementation entirely due to the complete absence of safety data in these populations.